AORT
$37.48
Artivion, Inc.
Intraday
Recent News
Stifel Remains a Buy on Artivion (AROT)
Artivion, Inc. (NYSE:AORT) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 5, Artivion, Inc. (NYSE:AORT) was reiterated with a Buy rating by analyst John McAulay of Stifel with a price target of $55. The analyst said in a research note that the Buy rating is based on […]
Envista, Baxter, Artivion, Dentsply Sirona, and Cigna Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
Shareholders Can Be Confident That Artivion's (NYSE:AORT) Earnings Are High Quality
Even though Artivion, Inc. ( NYSE:AORT ) posted strong earnings, investors appeared to be underwhelmed. Our analysis...
5 Must-Read Analyst Questions From Artivion’s Q4 Earnings Call
Artivion’s fourth quarter results were met with a negative market reaction, as revenue came in just below Wall Street’s expectations. Management attributed the quarter’s performance to robust demand for stent grafts, which grew 36% year-over-year, and continued gains from the On-X mechanical heart valve, which benefited from newly published clinical data. CEO Pat Mackin noted, “Growth was driven by our continued global market share gains and early traction in our new $100 million U.S. market opp
Why Artivion (AORT) Is Down 7.6% After Mixed Q4 Results And 2026 Guidance Above Consensus
In February 2026, Artivion, Inc. reported fourth-quarter and full-year 2025 results showing revenue rising to US$115.99 million for the quarter and US$441.33 million for the year, alongside a shift from losses to net income and positive earnings per share from continuing operations. Despite missing analyst revenue expectations, Artivion paired this profitability improvement with 2026 guidance above consensus and encouraging AMDS and NEXUS clinical data that support its longer-term aortic...